Vatalanib (hydrochloride)

• UNSPSC Description:

  Vatalanib (PTK787; ZK-222584; CGP-797870) hydrochloride is an inhibitor of VEGFR2/KDR with an IC50 of 37 nM[1].

• Target Antigen:

  Apoptosis; VEGFR

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Others; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/vatalanib-hydrochloride.html

• Solubility:

  10 mM in DMSO

• Smiles:

  ClC1=CC=C(NC2=NN=C(CC3=CC=NC=C3)C4=C2C=CC=C4)C=C1.[H]Cl

• Molecular Weight:

  383.27

• References & Citations:

  [1]Wood JM, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000;60(8):2178-2189.|[2]Murakami M, et al. Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells. Ann Surg Oncol. 2011;18(2):589-596.|[3]Wan J, et al. Local recurrence of small cell lung cancer following radiofrequency ablation is induced by HIF-1α expression in the transition zone. Oncol Rep. 2016;35(3):1297-1308.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 3

• CAS Number:

  212141-52-1